Enrolling patients affected by chronic kidney disease can be particularly challenging. With multiple comorbidities, they are often reluctant to undergo experimental research. Frenova’s access to a large study population allowed for the successful fulfillment of enrollment goals two months ahead of schedule in this multicenter global study.
